Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02209636 · ClinicalTrials.gov registry record · Phase 4
Phosphate Lowering in CKD Trial
A Phase 4 study of Cardiovascular Disease and Chronic Kidney Disease, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 4
- Development phase
- 66
- Enrollment target
- 1
- Study location
NCT02209636 is a Phase 4 study of Cardiovascular Disease and Chronic Kidney Disease that has completed, run by VA Office of Research and Development. The registered enrollment target is 66 participants, below the 2,713-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02209636, a Phase 4 study of Cardiovascular Disease and Chronic Kidney Disease, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 66 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed research is a randomized-controlled trial to determine the effectiveness of reducing serum phosphorus using a phosphate binder, lanthanum carbonate, for improving the function of arteries in adults with moderate to severe chronic kidney disease (CKD). \[COMIRB 13-0328\] Additionally, it will determine phosphorus balance among adults with CKD and whether there is a difference in phosphorus balance after three months of treatment with lanthanum carbonate. \[COMIRB 15-0384\]
Conditions Studied
Interventions
- DRUG placebo
- DRUG Ascorbic Acid
- DRUG Nitroglycerin
- DRUG Lanthanum carbonate
- PROCEDURE Flow-mediated dilation measurement
Study Locations (1)
Colorado
- Rocky Mountain Regional VA Medical Center, Aurora, CO - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2014-09-15 |
| Est. Completion | 2019-12-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02209636
The ClinicalTrials.gov registry entry for NCT02209636 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,713-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target (98% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cardiovascular Disease appearing as the primary indexed condition, and to 5 interventions - of which placebo is the first listed.
NCT02209636 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT02209636 about?
NCT02209636 is a clinical study titled "Phosphate Lowering in CKD Trial". The proposed research is a randomized-controlled trial to determine the effectiveness of reducing serum phosphorus using a phosphate binder, lanthanum carbonate, for improving the function of arteries in adults with moderate to severe chronic kidney disease (CKD). \[COMIRB 13-0328\] Additionally, it...
What is the current status of trial NCT02209636?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 66 participants. The study started on 2014-09-15. Estimated completion is 2019-12-20.
What conditions does trial NCT02209636 study?
This clinical trial studies the following conditions: Cardiovascular Disease, Chronic Kidney Disease.
What interventions are being tested in trial NCT02209636?
The interventions under investigation include: placebo (DRUG), Ascorbic Acid (DRUG), Nitroglycerin (DRUG), Lanthanum carbonate (DRUG), Flow-mediated dilation measurement (PROCEDURE).
Who is sponsoring clinical trial NCT02209636?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02209636 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Beta-Blocker Influences on Inflammatory and Neural Responses to Stress
RECRUITING · Phase 4
-
Randomized Trial of SGLT2i in Heart Transplant Recipients
RECRUITING · Phase 4
-
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
ACTIVE NOT RECRUITING · Phase 4
-
MIcrovascular dysfuNction In Moderate-severe Psoriasis
COMPLETED · Phase 4
-
Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)
COMPLETED · Phase 4
-
Bupropion for Hospitalized Smokers With Acute Cardiovascular Disease
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.